|Bid||580.00 x 0|
|Ask||0.00 x 0|
|Day's range||570.10 - 582.40|
|52-week range||400.20 - 582.40|
|Beta (5Y monthly)||0.32|
|PE ratio (TTM)||31.53|
|Forward dividend & yield||9.10 (1.73%)|
|Ex-dividend date||26 Mar 2021|
|1y target est||326.96|
Bagsværd, Denmark, 26 July 2021 – On 7 May 2021, Novo Nordisk initiated a share repurchase programme in accordance with Article 5 of Regulation No 596/2014 of the European Parliament and Council of 16 April 2014 (MAR) and the Commission Delegated Regulation (EU) 2016/1052 of 8 March 2016 (the "Safe Harbour Rules"). This programme is part of the overall share repurchase programme of up to DKK 18 billion to be executed during a 12-month period beginning 3 February 2021. Under the programme initiat
Novo Nordisk (NYSE: NVO) recently announced that it's buying Prothena's (NASDAQ: PRTA) transthetyrin amyloidosis (ATTR) cardiomyopathy program for up to $1.2 billion. In this Motley Fool Live video recorded on July 14, 2021, Motley Fool contributors Keith Speights and Brian Orelli discuss why Novo, which is best known for its diabetes franchise, is buying a rare-disease drug candidate. There is a company, I don't know that we've talked about much, if at all in the past, Brian, Novo Nordisk.
Novo Nordisk (NVO) and Eli Lilly (LLY) announce small acquisition deals. J&J (JNJ) recalls some consumer products.